Breaking News Instant updates and real-time market news.

OPK

OPKO Health

$10.20

-0.24 (-2.30%)

11:32
11/23/16
11/23
11:32
11/23/16
11:32

OPKO Health announces U.S. launch of RAYALDEE

OPKO Health announced that it will commence shipments of RAYALDEE extended-release capsules to distributors in the United States on Tuesday, November 29. The product will be available nationwide at retail pharmacies as early as Wednesday, November 30, the company said. Phillip Frost, M.D., CEO and Chairman of OPKO, said, "RAYALDEE is the first product developed by OPKO to be commercialized by our own marketing and sales teams, and represents an important contribution to the care of patients with chronic kidney disease. Based on the highly positive reception of RAYALDEE by nephrologists attending the recent ASN meeting, we believe that RAYALDEE will become a mainstay in the armamentarium of treatment options available for kidney disease patients."

OPK OPKO Health
$10.20

-0.24 (-2.30%)

03/31/16
JEFF
03/31/16
NO CHANGE
Target $11
JEFF
Hold
Uncertainty may persist after Opko's Health drug setback, says Jefferies
Jefferies analyst Brandon Couillard says the FDA's complete response letter to Opko's Health's New Drug Application for Rayaldee as a treatment for secondary hyperparathyroidism was a surprise. While nonfatal, the analyst believes the setback adds a new level of uncertainty around a key value driver that could weigh on the stock well into the second half of 2016. Couillard has a Hold rating and $11 price target on the shares.
04/27/16
LTCO
04/27/16
NO CHANGE
Target $20
LTCO
Buy
OPKO Health resubmission of Rayaldee lifts overhang, says Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter believes OPKO Health resubmission of the New Drug Application for Rayaldee, which he notes came roughly within the timeframe he expected, lifts a potential overhang on the stock. The acceptance of the resubmission and issuance of a new PDUFA date suggest the issues identified by FDA at the third party supplier was limited and a suitable plan has been communicated, DeGeeter tells investors. The analyst keeps a Buy rating and $20 price target on OPKO shares.
06/03/16
STPT
06/03/16
INITIATION
Target $16
STPT
Buy
OPKO Health initiated with a Buy at Standpoint Research
Target $16.
10/07/16
JEFF
10/07/16
NO CHANGE
Target $10
JEFF
Hold
Palmetto no-coverage decision 'major setback' for OPKO, says Jefferies
Jefferies analyst Brandon Couillard views Palmetto's no-coverage decision yesterday for OPKO Health's 4Kscore prostate cancer test as a "major setback." Palmetto is a Medicare administrative contractor. The analyst views 4Kscore as a key near-term growth driver for OPKO and believes the company's local Medicare administrative contractor Novitas will likely follow suit. Without Medicare, 4K's commercial pathway from here is unclear, Couillard tells investors in a research note. He expects OPKO shares to trade lower on renewed reimbursement concerns. The analyst has a Hold rating on the name.

TODAY'S FREE FLY STORIES

GRPN

Groupon

$4.53

0.14 (3.19%)

06:05
09/22/17
09/22
06:05
09/22/17
06:05
Initiation
Groupon initiated  »

Groupon initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECOM

ChannelAdvisor

06:04
09/22/17
09/22
06:04
09/22/17
06:04
Initiation
ChannelAdvisor initiated  »

ChannelAdvisor initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 03

    Oct

  • 04

    Oct

PG

Procter & Gamble

$92.64

-1.76 (-1.86%)

06:04
09/22/17
09/22
06:04
09/22/17
06:04
Hot Stocks
Trian identifies numerous errors in recent Procter & Gamble presentation »

Trian Fund, whose…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHUBA

CommerceHub

$23.42

-0.06 (-0.26%)

06:04
09/22/17
09/22
06:04
09/22/17
06:04
Initiation
CommerceHub initiated  »

CommerceHub initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

EVLV

Evine Live

$1.03

0.01 (0.98%)

06:02
09/22/17
09/22
06:02
09/22/17
06:02
Initiation
Evine Live initiated  »

Evine Live initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

  • 16

    Nov

AMZN

Amazon.com

$964.65

-8.56 (-0.88%)

06:01
09/22/17
09/22
06:01
09/22/17
06:01
Hot Stocks
Amazon to add 359,000 square foot office in New York City »

Governor Andrew M. Cuomo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

ICPT

Intercept

$73.70

-24.42 (-24.89%)

06:01
09/22/17
09/22
06:01
09/22/17
06:01
Downgrade
Intercept rating change  »

Wells yesterday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$171.11

-1.06 (-0.62%)

05:55
09/22/17
09/22
05:55
09/22/17
05:55
Hot Stocks
Instagram adds Face Filters to live video, to roll out globally »

Instagram says in a blog…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

PSTG

Pure Storage

$15.02

0.19 (1.28%)

05:55
09/22/17
09/22
05:55
09/22/17
05:55
Recommendations
Pure Storage analyst commentary  »

Pure Storage price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

AABA

Altaba

$66.59

-0.33 (-0.49%)

, BABA

Alibaba

$177.39

-0.56 (-0.31%)

05:52
09/22/17
09/22
05:52
09/22/17
05:52
Recommendations
Altaba, Alibaba, Yahoo Japan analyst commentary  »

Altaba price target…

AABA

Altaba

$66.59

-0.33 (-0.49%)

BABA

Alibaba

$177.39

-0.56 (-0.31%)

YAHOY

Yahoo Japan

$8.90

-0.08 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

REPYY

Repsol

$18.47

0.1 (0.54%)

05:52
09/22/17
09/22
05:52
09/22/17
05:52
Upgrade
Repsol rating change  »

Repsol upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$21.60

-0.25 (-1.14%)

05:49
09/22/17
09/22
05:49
09/22/17
05:49
Downgrade
Versartis rating change  »

Versartis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRPIF

BRP Inc.

05:48
09/22/17
09/22
05:48
09/22/17
05:48
Upgrade
BRP Inc. rating change  »

BRP Inc. upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$92.64

-1.76 (-1.86%)

05:47
09/22/17
09/22
05:47
09/22/17
05:47
Hot Stocks
Glass Lewis recommends Procter & Gamble holders vote for Nelson Peltz »

Trian Fund Management,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$12.27

-0.07 (-0.57%)

05:46
09/22/17
09/22
05:46
09/22/17
05:46
Recommendations
MiMedx analyst commentary  »

MiMedx shares offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

BA

Boeing

$256.04

0.58 (0.23%)

05:45
09/22/17
09/22
05:45
09/22/17
05:45
Hot Stocks
Boeing sees growing demand for new airplanes in Southeast Asia »

Boeing projects a demand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

05:45
09/22/17
09/22
05:45
09/22/17
05:45
General news
Breaking General news story  »

San Francisco Federal…

SSNI

Silver Spring

$16.15

0.01 (0.06%)

, ITRI

Itron

$75.85

-0.4 (-0.52%)

05:40
09/22/17
09/22
05:40
09/22/17
05:40
Downgrade
Silver Spring, Itron rating change  »

Silver Spring downgraded…

SSNI

Silver Spring

$16.15

0.01 (0.06%)

ITRI

Itron

$75.85

-0.4 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$41.62

-3.59 (-7.94%)

05:38
09/22/17
09/22
05:38
09/22/17
05:38
Syndicate
Juno Therapeutics 6.1M share Secondary priced at $41.00 »

Morgan Stanley and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 22

    Sep

AA

Alcoa

$46.25

-1.25 (-2.63%)

05:38
09/22/17
09/22
05:38
09/22/17
05:38
Downgrade
Alcoa rating change  »

Alcoa downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOBE

Bob Evans

$77.29

-0.2 (-0.26%)

, POST

Post Holdings

$86.97

-0.39 (-0.45%)

05:38
09/22/17
09/22
05:38
09/22/17
05:38
Downgrade
Bob Evans, Post Holdings rating change  »

Bob Evans downgraded to…

BOBE

Bob Evans

$77.29

-0.2 (-0.26%)

POST

Post Holdings

$86.97

-0.39 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$153.39

-2.68 (-1.72%)

05:36
09/22/17
09/22
05:36
09/22/17
05:36
Recommendations
Apple analyst commentary  »

Piper ups Apple target to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

TIF

Tiffany

$89.85

-0.08 (-0.09%)

05:31
09/22/17
09/22
05:31
09/22/17
05:31
Downgrade
Tiffany rating change  »

Tiffany downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

, VSAR

Versartis

$21.60

-0.25 (-1.14%)

05:27
09/22/17
09/22
05:27
09/22/17
05:27
Recommendations
Ascendis Pharma, Versartis analyst commentary  »

Versartis failure bodes…

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$191.56

-2.44 (-1.26%)

, BCR

C.R. Bard

$317.37

-1.19 (-0.37%)

05:20
09/22/17
09/22
05:20
09/22/17
05:20
Initiation
Becton Dickinson, C.R. Bard initiated  »

Becton Dickinson…

BDX

Becton Dickinson

$191.56

-2.44 (-1.26%)

BCR

C.R. Bard

$317.37

-1.19 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.